Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone: an eastern cooperative oncology group study
Antineoplastic Agents, Hormonal
Neoplasms, Glandular and Epithelial
Proto-Oncogene Proteins c-kit
Receptor, Epidermal Growth Factor
High EGFR immunoreactivity is seen in more aggressive thymic neoplasms as classified according to the 2004 WHO, but regardless of classification, the presence of EGFR in tumor cells (1+, 2+, and 3+) is associated with improved performance free survival (PFS) and a trend for better OS. In contrast, the absence of C-kit immunoreactivity was associated with improved PFS. These data suggest that EGFR and C-kit may be prognostic, and further studies of these markers in subcategories of thymic malignancies is warranted.